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Abstract: Objective: To assess long-term results and present experience with a high-porosity hydroxya-
patite ceramic for obliterating large open mastoid cavities. Study-Design: Cross-sectional cohort study.
Setting: Tertiary academic referral center. Patients: All patients who underwent tympanomastoid surgery
for chronic middle ear disease or revision surgery with reduction of an open mastoid cavity using a highly
porous hydroxyapatite matrix material (HMM) between May 2005 and June 2013 were assessed for eligi-
bility. Twenty three patients (56.9 ± 18.3 yr) were included. Intervention: Primary middle ear surgery
or revision surgery using a HMM. Main Outcome Measures: Pure-tone average, computed tomogra-
phy (CT), and magnetic resonance imaging (MRI) to investigate osseoinduction, osseointegration and
presence of cholesteatoma, current quality of life assessed by Zurich Chronic Middle Ear Inventory and
change in quality of life post-intervention assessed by the Glasgow Benefit Inventory. Results: Patients
were reexamined after a mean follow-up period of 88.3 months (SD 21.4 mo) after obliteration of the
open mastoid cavity with HMM. Compared with visit 1, patients showed a significantly reduced ABG
at visit 2 (29.22 dB ± 2.71 dB versus 12.77 dB ± 3.46 dB). CT scan was carried out in 21 patients
(91%) patients and 17 patients (74%) underwent MRI. Revision surgery was required in a total of 17
cases (74%). In four patients recurrent cholesteatoma was found at follow up. Conclusions: Poor cavity
obliteration, a high rate of revision surgery and difficult differentiation between recurrent cholesteatoma
and granulation tissue in CT scan was observed.
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Objective: To assess long-term results and present experi-
ence with a high-porosity hydroxyapatite ceramic for obliter-
ating large open mastoid cavities.
Study-Design: Cross-sectional cohort study.
Setting: Tertiary academic referral center.
Patients: All patients who underwent tympanomastoid sur-
gery for chronic middle ear disease or revision surgery with
reduction of an open mastoid cavity using a highly porous
hydroxyapatite matrix material (HMM) between May 2005
and June 2013 were assessed for eligibility. Twenty three
patients (56.9 18.3 yr) were included.
Intervention: Primary middle ear surgery or revision surgery
using a HMM.
Main Outcome Measures: Pure-tone average, computed
tomography (CT), and magnetic resonance imaging (MRI) to
investigate osseoinduction, osseointegration and presence of
cholesteatoma, current quality of life assessed by Zurich
Chronic Middle Ear Inventory and change in quality of life
post-intervention assessed by the Glasgow Benefit Inventory.
Results: Patients were reexamined after a mean follow-up
period of 88.3 months (SD 21.4 mo) after obliteration of the
open mastoid cavity with HMM. Compared with visit 1,
patients showed a significantly reduced ABG at visit 2
(29.22 dB 2.71 dB versus 12.77 dB 3.46 dB).
CT scan was carried out in 21 patients (91%) patients and
17 patients (74%) underwent MRI.
Revision surgery was required in a total of 17 cases (74%).
In four patients recurrent cholesteatoma was found at follow
up.
Conclusions: Poor cavity obliteration, a high rate of revision
surgery and difficult differentiation between recurrent choles-
teatoma and granulation tissue in CT scan was observed.
Key Words: Allogeneic bone pate—Cholesteatoma—
Chronic middle ear disease—High-porosity hydroxyapatite
ceramic—Open mastoid cavity obliteration.
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Tympanoplasty is performed in patients with chronic
middle ear disease, e.g., cholesteatoma or chronic otitis
media, to restore the tympanic membrane and the sound
conduction system, but also in patients with previous ear-
surgery, where the ossicles were involved in the disease,
to achieve better hearing performance. In case of an
extension of the cholesteatoma into the mastoid, canal
wall up versus canal wall down techniques are differen-
tiated. Reasons for the creation of an open mastoid cavity
can be the extend of cholesteatoma or the inflammation
process. Depending on the extend of the open mastoid
cavity and the meatal size, the self-cleaning process can
be disturbed, leading to recurrent ear-infections, secre-
tion, vertigo, hearing impairment, and frequent consul-
tation of an ENT-specialist (1).
In these cases, the treatment of choice consists of
surgical obliteration of the open mastoid cavity in com-
bination with a meatoplasty. Multiple methods and mate-
rials for obliteration have been developed (2). Usually,
the use of autologous material is preferred due to its good
biocompatibility. Cartilage, either from the concha, tra-
gus or nasal septum, muscle-flaps, bone-pâté, or fascia
can be used. Negative aspects can be the natural shrink-
age and the limited availability of autologous material
after repeated revision surgery (3). For this reason,
diverse xenografts and alloplastic materials have been
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designed and tested (4,5). However, the mechanism of
the biomaterial-based regeneration process is still mostly
unexplored.
Alloplastic material is easily available but causes
additional material expenses to the healthcare system.
In addition, wound infections due to rejection reactions,
granulations, and inflammation reactions have been
described (2,6). On the other hand, alloplastic materials
could save surgical time for harvest and reduce comor-
bidities at the donor side.
Highly porous hydroxyapatite matrix material (HMM)
is frequently used in maxillofacial surgery and showed
stable long-term results in a 3-year-follow-up investiga-
tion of implant stability (7). Histological and histomor-
phometric changes in clinical application of synthetic
(HMM) and xenogeneic bone substitute (XBM)materials
in head and neck cancer patients showed significantly
greater vascularization and a higher number of multinu-
cleated giant cells in the HMM group compared with the
XBM group. HMM was degraded by the multinucleated
giant cells and replaced mainly by connective tissue,
whereas XBM remained in the implantation bed, serving
as a spacer (8). Animal experiments demonstrated that
the vascularization and biodegradation in the HMM
implantation bed reached its peak after 10 days with
relatively few multinucleated giant cells and macro-
phages. Mononuclear cells, such as macrophages, were
also found on the bone substitute material (9,10). Histo-
logical investigations of the synthetic bone substitute
material HMM used in humans for paranasal sinus
augmentation showed integration of the granules into
the host tissue 6 months after augmentation as well as
newly formed bone in all parts of the augmented region
(11,12).
First experience with an alloplastic material consisting
of hydroxyl-apatite matrix (HMM) show a good biocom-
patibility in animal experiments after implantation into
adipose neck tissue of rats (13) and into guinea pig bullae
(14,15). In a number of consecutive animal and clinical
trials, HMMhas been investigated with regard to the basis
of its physiochemical structure and integration in animal
implantation models as well as in human tissue (7–12).
Short term clinical results (29 mo) of 20 patients after
mastoid cavity obliteration with HMM showed an
uneventful healing and a reduction of vertigo, otorrhea,
and frequency of medical consultation (16). Literature
review regarding the revision rate at long-term follow up
after open mastoid cavity reduction identifies many
studies on follow up of patients after a period of 2 years
or later using autologous material but only few data is
available on long-term results with allogeneic material
(Table 1). Revision rates between 0 and 38% are
reported. HMM resulted in high complication rates with
a rejection rate of 20% in a case population of n¼ 18 (17).
We hypothesize that the clinical follow-up for choles-
teatoma after obliteration of an open mastoid cavity using
HMM is disturbed by the consistence and the surrounding
cellular reaction induced by HMM impeding the differ-
entiation between allograft and recurrent cholesteatoma
in radiologic and clinical follow-up examinations. The
aim of this study was to analyze the long-term results of
patients receiving HMM after tympanomastoid surgery
with regard to the identification of recurrent cholestea-
toma, changes in tomography imaging, number and




The study protocol was approved by the local Ethics Com-
mittee in accordance with the Helsinki declaration (registration-
number: A2017–0101). Informed consent was obtained from
all the participants.
Study Design and Patient Selection
In this cross-sectional cohort study, patients receiving open
mastoid cavity obliteration using HMM between May 2005 and
June 2013 were assessed for inclusion (Fig. 1). Patients were
recruited from a tertiary hospital, a university medical center.
Visit 1 was defined as preoperative investigation before the
obliteration of themastoid cavity with HMM, visit 2 as the latest
follow-up available.
Patients included in the study underwent MRI and CT
imaging, pure-tone audiometry and completed two question-
naires (see below) as part of the current study at visit 2. Further,
a retrospective chart review was carried out, including assessing
previous ear surgery (primary versus revision), the condition of
the tympanic membrane (intact versus defect), and the presence
of cholesteatoma at the time of surgery.
Bone Grafting Substitute
NanoBone (Artoss GmbH, Rostock, Germany) is a fully
synthetic bone substitute granule, it consists of hydroxyapatite
crystallites with an average size of 60 nm in each crystallo-
graphic direction that are embedded in a matrix of silica gel
(18). It is produced by a sol–gel technique at temperatures
below 700 8C, avoiding sintering of the nanocrystalline
hydroxyapatite (18). The biomaterial is characterized by open
bonds that are responsible for an internal surface of up to 84m2/
g in size. The pore size distribution within the silica gel ranges
from 10 to 20 nm in diameter. Macroscopically, the granules
have a length of around 2mm and diameter of 0.6mm.
Audiometric Assessment
All audiometric measurements were performed with cali-
brated instruments in a sound-proof room (DIN EN ISO 8253).
Measurements included standard pure-tone audiometry (air
conduction: 0.25–8 kHz; bone conduction: 0.5–6 kHz), per-
formed with a clinical audiometer (AT1000, Auritec, Hamburg,
Germany) by an experienced audiologist in 5 dB steps. Oper-
ators were blinded with respect to the type of intervention. Air-
bone gaps (ABG) were calculated as the difference between the
pure-tone averages of the air-conduction thresholds measured at
0.5, 1, 2, and 3 kHz (PTA0.5–3 kHz) and the respective average
bone conduction thresholds. According to recommendations
in hearing reporting standard (19) and to the Committee on
Hearing Equilibrium guidelines (20), the ABG0.5–3 kHz was
chosen for evaluating the results of treating conductive hearing
loss. Therefore, only the ABG0.5–3 kHzwas further analyzed and
is referred to as ABG. Preoperative audiometric results (visit 1)
and at the latest follow-up (visit 2) were collected.
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Radiological Assessment
All CT examinations were performed on a 64-row CT
scanner (Aquillion 64, Canon Medical, Tustin, CA). Represen-
tative CT imaging protocol was the following: volumetric
acquisition from above the ear below the level of the skull
base; 120 kV, 150mA. All CT dataset were reconstructed in
axial and coronal planes in bone window/level settings with a
standard field-of-view (FoV; 22 cm) with a slice thickness of
1mm and a slice gap of 0.5mm.
All MR examinations were performed at 1.5T (Avanto Fit,
Siemens Medical System, Erlangen, Germany) using a 20
channel head coil for signal detection. Following the localizer,
an axial T1-weighted (T1w) Spin Echo (SE) sequence was
acquired. Imaging parameters were time of repetition (TR)/time
of echo (TE) 450/8.5ms, FoV 180mm, matrix size 192 256
with an in-plane resolution 0.7 0.7mm and a slice thickness
of 3mm. Next, a coronal T2-weighted (T2w) Turbo Spin Echo
(TSE) sequence was acquired (imaging parameters: TR/TE
3500/79ms, FoV 170mm, matrix 192 256, in-plane resolu-
tion 0.3 0.3mm, slice thickness 3mm) followed by a T2w
HASTE (Half Fourier Single shot TSE) diffusion weighted
sequence with one b-value b¼ 1000mm/s2 (imaging parame-
ters: TR/TE 2000/103ms, FoV 200mm, matrix 144 192, in-
plane resolution 0.5 0.5mm, slice thickness 3mm). After
contrast administration of 0.1mmol gadobutrol (Gadovist,
Bayer, Germany) per kg bodyweight a T1w VIBE (Volume
Interpolated Breathold Examination) with fat suppression
(imaging parameters: TR/TE 9/2.38ms, FoV 200mm, matrix
192 256, in-plane resolution 0.8 0.8mm, slice thickness
0.8mm) with multiplanar reconstructions in coronal plane
was acquired.
Questionnaires
The Zurich Chronic Middle Ear Inventory (ZCMEI-21) was
used to assess current quality of life (21). The ZCMEI-21
consists of four subscales concerning ear signs and symptoms,
hearing function, psychosocial impact, and the use of medical
resources. Answers are presented using a five-point Likert-
scale. High scores correlate with a poorer quality of life (21).
The ZCMEI-21 was designed as a disease-specific instrument
to assess health-related quality of life in patients suffering from
chronic middle ear disease and may also be used after surgical
interventions. To assess change in quality of life after surgery,
the Glasgow Benefit Inventory (GBI) was used (22). The GBI is
a well-studied and validated outcome instrument that was
proved to be maximally sensitive to otosurgical interventions.
Responses to the GBI are based on a five-point Likert-scale.
Scores range on a benefit-scale from 100 (maximal negative
effect) to 0 (no effect) to þ100 (maximal positive effect).
Statistical Analysis
All statistical tests were selected before data collection.
Statistical analyses were performed using Microsoft Excel
and Prism (version 7, GraphPad Software, La Jolla, CA).
The significance level was set to p< 0.05. The assumption
of normality in ABG distributions was tested using visual
inspection as well as the D’Agostino-Pearson normality test.
If not otherwise specified, data are presented as mean with
standard deviation (SD) or absolute numbers with percentages.
RESULTS
A total of 36 patients receiving tympanomastoid sur-
gery using HMM between 2005 and 2013 were assessed
for inclusion, of which 23 patients were available for
follow-up investigation (16 women and 7 men; mean age
56.9 yr, 12 right and 11 left ears) and were analyzed.
Cholesteatoma was the underlying chronic middle ear
disease in every case. The open mastoid cavity was either
preexisting or it was created during surgery. Median
interval between the creation of the open mastoid cavity
and the obliteration with HMM was 22.6 17.1 years. In
only one case, the mastoid cavity was created during
Findings (n = 17)
Patients assessed for eligibility (chart review; n = 36)
Open mastoid obliteration with HMM between May 2005 and June 2013
Patients excluded (n = 13)
Unavailable for follow-up
Declined to participate
Patients included (n = 23)
No apparent disease (n = 6)
HMM removal during 
earlier surgery (n = 4)
HMM in place at 
follow-up (n = 13)
Total
Indication for revision
Cholesteatoma 3/4 7/13 10/17
Insufficient cavity reduction 1/4 9/13 10/17
Perforation 0/4 1/13 1/17
FIG. 1. Study flow chart; CT not available in n¼2 patients where the HMM had already been removed during previous surgery; MRI not
available in n¼6 due to contraindications for MRI-investigation or due to bad physical conditions. CT indicates computed tomography;
HMM, hydroxyapatite matrix material; MRI, magnetic resonance imaging.
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surgery and obliterated during the same procedure. In the
remaining 22 cases, the cavity was preexisting from
previous tympanomastoid surgery. The mean time period
between the obliteration of the open mastoid cavity and
the follow-up visit was 7.4 1.8 years. A total of eight
patients (35%) had revision surgery in the time between
the HMM obliteration and the last follow-up investiga-
tion. In four cases (17%), the HMM obliteration material
had already been removed during previous surgeries,
leaving 19 patients (83%) with remaining HMM in the
mastoid cavity. The reasons for removal of the bone
substitute were recurrent cholesteatoma in three cases
and an insufficient cavity reduction in one case.
Compared with visit 1, i.e., the preoperative visit,
patients showed a significantly reduced ABG at visit
2, i.e., the latest follow-up available (mean difference
16.45 4.39 dB, p¼ 0.0005; Fig. 2A). No significant
difference was found between the bone conduction
thresholds at visit 1 and visit 2 (mean difference
8.2 dB, p¼ 0.08; Fig. 1B). The presence of cholestea-
toma and the status of the tympanic membrane (defect
versus intact) by the time of surgery did not have a
significant influence on the audiological outcome
defined as ABG shift.
At visit 2, 11 patients (48%) had a positive test of
Valsalva, seven patients (30%) reported to suffer from
otorrhea, three patients (13%) complained about recur-
rent otalgia, seven patients (30%) about tinnitus and
seven patients (30%) about caloric induced vertigo. In
only one case (4%), the tympanic membrane reconstruc-
tion was perforated, in the remaining 22 cases (96%), it
was intact. In 17 cases (74%), the mastoid cavity was dry,
in two cases (9%), there were signs of an infection, and in
four cases (17%), the extent of the mastoid cavity was not
completely visible. Revision surgery was indicated in
nine cases (39%). In four cases (17%) revision surgery
was indicated due to recurrent cholesteatoma, in the other
cases to reduce the cavity size, due to chronic infections
and for hearing-improvement. In one case a perforation
of the tympanic membrane was found additionally. In all
of those cases, the obliteration material was still in place.
The cavity was sufficiently obliterated and observable in
only nine cases (39%) at follow-up. Together with the
revision surgeries that had been performed in the time
between the initial surgery with HMM and the follow-up,
a total number of 17 patients (74%) had to be revised after
the open mastoid cavity obliteration with HMM, leaving
only a number of six patients (26%) without apparent
disease (Fig. 1).
CT scans were conducted in 21 patients (91%) patients
and 17 patients (74%) underwent MRI including non-epi
diffusion weighted imaging (HASTE-DWI). In one case
neither CT nor MRI was possible due to the poor physical
condition. In six cases (26%), MRI was not possible due
to either non-MRI safe implants (e.g., pacemakers) or due
to allergies to contrast enhancers. In four cases, the
diagnosis of recurrent cholesteatoma was made clini-
cally, i.e., by otoscopic inspection. In these cases,
HASTE sequence showed signs for cholesteatoma in
only one case (25%). In seven cases (30%), CT imaging
showed soft tissue in the mastoid.
Figure 3 shows the CT- and MRI-scans of an exem-
plary patient, where the HMM is well integrated. Cra-
niodorsally, a soft tissue cover can be seen as marked by
the arrow (Fig. 3B). The MRI shows no signs of choles-
teatoma (Fig. 3C, D). The same patient underwent revi-
sion surgery because of retraction pockets in the
tympanic cavity (Fig. 3E–G). The HMM was partially
removed and replaced using autologous material.
Figure 4 illustrates the time-course of a patient, who
had CT-scan before and twice after revision surgery due
to clinically suspected cholesteatoma with otorrhea.
Figure 4A shows the CT-scan previous 1st revision
surgery where an irregular surface of the obliteration
material indicates recurrent cholestetoma. Revision sur-
gery was performed due to recurrent cholesteatoma.
Three years after revision surgery (Fig. 4B) and 7 years

















































Mastoid cavity obliterationA B
FIG. 2. Audiometric results A, air-bone gap (ABG0.5–3 kHz) before and after mastoid cavity obliteration. B, Bone conduction threshold
before and after mastoid cavity obliteration. Bold line indicates mean, error bars indicate standard deviation.
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remains stable and a continuous integration and a discrete
shrinkage can be seen. Figure 4D shows the histology of
the resection material of the same patient. The material
shows a partially integrated HMM with adjacent connec-
tive tissue.
At visit 2, mean ZCMEI-21 score was 26.6 13.2,
which corresponds to a mildly to moderately impaired
quality of life (21,23). Mean GBI score was 0.3 15.0
indicating neither a positive nor a negative subjective
effect of the surgery (Fig. 5).
FIG. 3. CT- and MRI-scans as well as intraoperative pictures of revision surgery of one of the patients, with the HMM still in place. A, CT
axial view, B, CTcoronar view, C, coronar MRI in T2-sequence, D, coronar MRI in T1-sequence. A/B Craniodorsally, a soft tissue formation
can be seen as marked by the arrow (B, C, and D). The MRI shows no hints for cholesteatoma. Intraoperatively, the HMM marked by the
arrow inE and Fwas removed and the openmastoid cavity was reduced using autologousmaterial (G). CT indicates computed tomography;
HMM, hydroxyapatite matrix material; MRI, magnetic resonance imaging.
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DISCUSSION
This is the first long-term investigation of patients
where HMM was used for obliteration of open mastoid
cavities investigating a time period of this extent. Notice-
able was the high number of persistent discharging and
poorly observable mastoid cavities.
Open mastoid cavity reduction is performed to
improve the patient’s quality of life by reducing the
amount of caloric vertigo, otorrhea as well as to reduce
the frequency of consultation of an ENT-specialist (6).
This aim was achieved in only 39% of the patients in this
study. A study investigating the GBI-score after open
mastoid cavity obliteration with autologous bone showed
a significant improvement in the QoL (24). In this cohort,
the total GBI-score, describing the subjective benefit
from the mastoid obliteration showed a mean of
0.3 15.0, indicating no subjective benefit at all accord-
ing to the clinical observations. The scores correlated
well with the ZCMEI-21-scores, a newly evaluated ques-
tionnaire investigating the patient’s quality of life con-
cerning chronic middle-ear diseases.
For surgery, autologous and alloplastic materials are
used. HMM is an evolved hydroxyapatite material that
has been used successfully in maxillofacial surgery (25).
It is rarely used in ENT-surgery for open mastoid cavity
obliteration. The hydroxyapatite bone substitute is said to
have an osseogenetic effect that was proven in an animal
experiment (26). New bone formation could be observed
in clinical trials after 3 months already, making the
material attractive with respect to wound healing and
low rejection reactions (12). The supporting arguments
for allogeneic material are its lack of shrinkage and the
easy access (14–16).
Studies on cellular changes induced by the material
showed a significant degradation of the material due to
macrophage, giant-cell, and lymphocyte absorption lead-
ing to material shrinkage and like that to an insufficient
material substitution (9,27). This observation is compre-
hensive and substantiated, regarding data of the present
study. The large majority of patients was found to have a
persistent open mastoid cavity at the follow-up visit and
in the CT scan, leading to the assumption, that the
obliteration material was either used hesitantly or that
osseointegration leads to shrinkage.
Ghanaati et al. (10) showed in his histological studies,
that there is no osseoinduction by the material, contrary
to the suspected opinions mentioned above. Additionally,
it showed, that part of the material was resorbed by
macrophages and giant cells, leading to the formation
of fibrous tissue rather than bone, thus making the
postoperative discrimination between fibrous tissue
and recurrent cholesteatoma difficult. This observation
was also made in 30% of the CT-scans in this study.
Since the covered mastoid cavity is not as easily
accessible for revision surgery, the lack of appropriate
follow-up opportunities differentiating between fibrous
tissue and cholesteatoma is regarded as disadvantageous.
CT examinations cause radiation exposure to the
patient and should therefore be avoided as follow-up
examinations on a regular basis. MRI, which is often
recommended to be highly sensitive in cholesteatoma
detection (28,29) and allows the differentiation between
scar tissue formation and recurrent cholesteatoma, cannot
be performed in patients with non-MRI-safe implants as
seen in six patients in our study or in case of other
contraindications. Furthermore, MRI is of limited value
in the evaluation of the bony structures of the skull base
and the possible osseous integration of the obliteration
material. Small cholesteatomas cannot always be suffi-
ciently identified (29). Finally, from the socio-economic
point of view, MRI is cost-intensive for routine follow-
up imaging if there are no clinical signs of recurrent
cholesteatoma.
Comparing our results to other studies, large analyses
of open mastoid cavity obliteration with different oblit-
eration-materials showed rejection responses of hydroxy-
apatite (HA) and confirmed a higher revision rate
compared with bone or cartilage (17). In this cohort,
the rate of revision surgery was exceptionally high (74%)
compared with other long-term follow-up investigations
as seen in Table 1. Thus leading to the assumption, that
the longer the follow-up period is chosen, the more often
complications occur.
As a consequence, it can be assumed, that HMM
itself is a stable and biocompatible material for bone
FIG. 4. Time-course of HMM in the CT-scan and histological appearance: A shows the preoperative CT-scan before revision surgery
showing an irregular surface of the obliteration material. B, Postoperative control in 2014 and C, in 2018. The appearance of the material
remains stable and a continuous integration and a discrete shrinkage can be seen. D, Histology of the HMM in hematoxylin-eosin stain,
showing a partially integrated HMM with adjacent connective tissue. ( bone,  HMM, # connective tissue, þ capillary). CT indicates
computed tomography; HMM, hydroxyapatite matrix material.
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replacement outside the mastoid but does not positively
influence the course of the chronic middle ear disease. It
can be useful in cases where multiple revision surgeries
are necessary with lacking opportunities for autologous
material, but we assume, that the use is challenging
concerning the correct dosage of the material. Not leav-
ing the cavity too narrow has to be weighed against the
correct amount needed for sufficient cavity reduction and
has also not to be underestimated.
CONCLUSION
In this study, a poor cavity obliteration and a high rate
of revision surgery (74%) was observed at late follow-up
(visit 2) in this study group. The material was proved to
be a good bone substitute material outside the mastoid. In
the case of cholesteatoma-surgery, it has to be regarded
critically since cholesteatoma is a chronic disease with
several microbiological aspects involved. The cholestea-
toma and the accompanying inflammation of the peri-
matrix can lead to an infiltration of the bone around the
HMM. The keratinizing squamous epithelium of the
cholesteatoma does not lead to resorption of the material
but forms biofilms on the HMM that can be an additional
reason for the high rate of persistent superinfections of
the openmastoid cavity and the consecutive high revision
rate. A superiority to autologous material cannot be
assumed from these results.
The opportunities of tomography imaging for after-
care-options are limited. In CT scans, it was hard
to differentiate between recurrent cholesteatoma and
granulation tissue. This observation confirms other stud-
ies that showed, that further characterization between
soft-tissue and cholesteatoma needs additional MRI-
investigation (30). MRI is not able to detect small
cholesteatomas and is not accessible for every patient.
As a consequence, we conclude, that HMM is not
recommendable for the use in the mastoid, particular for
mastoid obliteration. These results should carefully be
taken into account by any surgeon considering an artifi-
cial agent to obliterate mastoid cavities.
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